BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31484281)

  • 1. [Clinicopathological features and prognosis of 488 patients with neuroendocrine tumors].
    Zhai XJ; Yu SL; Ma YH; Wang F; Yang MJ; Lian YJ; Yu XX; Fan QX; Song LJ
    Zhonghua Yi Xue Za Zhi; 2019 Aug; 99(32):2527-2531. PubMed ID: 31484281
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
    Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinicopathological characteristics and prognosis analysis of colorectal neuroendocrine neoplasms based on the data from domestic six medical centers].
    Zhang Y; Peng X; Jin K; Wang W; Feng X; Zeng Y; Chen M; Yu X; Chen Y; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1235-1240. PubMed ID: 27928792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
    Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
    Min BH; Hong M; Lee JH; Rhee PL; Sohn TS; Kim S; Kim KM; Kim JJ
    Br J Surg; 2018 Oct; 105(11):1480-1486. PubMed ID: 29893418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
    Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroendocrine tumors: analysis of 252 cases].
    Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.
    Kasajima A; Konukiewitz B; Schlitter AM; Weichert W; Klöppel G
    Virchows Arch; 2022 Feb; 480(2):359-368. PubMed ID: 34499237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
    Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single-center study.
    Song L; Zhai X; Yu S; Ma Y; Wang F; Yu X; Tao S; Lian Y; Yang M; Tao W; Fan Q
    Cancer Med; 2019 Jul; 8(8):3729-3737. PubMed ID: 31127690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
    Özaslan E; Demir S; Karaca H; Güven K
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
    Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
    Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
    Yao W; Wang W; Li G
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
    Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
    Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.